You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Combodart Indications

Combodart is indicated for the management of moderate to severe symptomatic benign prostatic
hyperplasia (BPH).
[1]
Combodart (dutasteride/tamsulosin hydrochloride) is the only registered fixed dose combination in Ireland for the treatment of moderate to severe BPH symptoms.
It is a combination of two medicines, dutasteride and tamsulosin hydrochloride.

Dutasteride:

  • lowers DHT levels,
  • reduces prostate volume,
  • improves lower urinary tract symptoms and urine flow
  • reduces the risk of Acute Urinary Retention (AUR) and BPH related surgery.

Tamsulosin:

  • increases maximum urinary flow rate by reducing smooth muscle tension in the prostate and urethra, thereby relieving obstruction.
  • improves the complex of irritative and obstructive symptoms in which bladder instability and tension of the smooth muscles of the lower urinary tract play an important role.
  • Alpha-1 adrenergic blockers can reduce blood pressure by lowering peripheral resistance

Sample Patient Profile

The following profile is an example of a patient type bothered by moderate BPH symptoms, including an enlarged prostate and impacted quality of life, whom you can start with Combodart.
This is a fictitious patient representing the CombAT study population[1]
IPSS = International Prostate Symptom Score.
PVol = Prostate Volume.

John – Moderate BPH

image of John

Complaints:

  • I get up to go to the toilet 2 to 3 times a night. It’s not only me that’s not rested, my partner also never gets a decent night’s sleep either
  • I have to go to the toilet a lot during the day. 
  • I try to avoid long meetings now as having to excuse myself repeatedly looks unprofessional
  • I spend more time in the toilet. It’s embarrassing taking so long, because of my weak urinary stream

Clinical profile:

  • IPSS: 16
  • PVol: 40cc
  • PSA: 1.9ng/mL

Reference:

  1. Roehrborn CG et al. Eur Urol 2010; 57: 123–131.

Combodart is registered trademark of the GlaxoSmithKline Group of companies